Reps. Henry Waxman, D-Calif., and Nathan Deal, R-Ga., introduced a proposal that would allow the FDA to approve generic versions of biotech medicines. The bill, which would give brand-name biotech drugs three to five years of market exclusivity, would "lead to healthy competition and long-term savings for patients and payers" and "preserve innovation in the biotech marketplace," Waxman said.

Full Story:
Reuters, Google

Related Summaries